TY  - GEN
AU  - Thaçi,D
AU  - Pinter,A
AU  - Sebastian,M
AU  - Termeer,C
AU  - Sticherling,M
AU  - Gerdes,S
AU  - Wegner,S
AU  - Krampe,S
AU  - Bartz,H
AU  - Rausch,C
AU  - Mensch,A
AU  - Eyerich,K
TI  - Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS)
SN  - 1365-2133
PY  - 2021///0514
KW  - Antibodies, Monoclonal
KW  - adverse effects
KW  - Antibodies, Monoclonal, Humanized
KW  - Fumarates
KW  - Humans
KW  - Psoriasis
KW  - drug therapy
KW  - Quality of Life
KW  - Severity of Illness Index
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1111/bjd.18696
ER  -